Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis.
Joshua F BakerJames R ODellBryant R EnglandJon T GilesJefferey A NewcombMichael D GeorgeGeoffrey M ThieleLarry MorelandS Louis BridgesJeffrey R CurtisTed R MikulsPublished in: Annals of the rheumatic diseases (2024)
Lower BMI and evidence of lower adiposity based on adipokine profiles were associated with a superior response to TNFi compared with triple therapy. There was no difference between treatments among overweight/obese participants. The results support TNFi being a particularly important therapeutic among normal/underweight patients, with implications for clinical decisions and trial design.
Keyphrases
- rheumatoid arthritis
- weight gain
- weight loss
- insulin resistance
- metabolic syndrome
- type diabetes
- clinical trial
- body mass index
- physical activity
- randomized controlled trial
- study protocol
- stem cells
- phase iii
- disease activity
- bariatric surgery
- systemic lupus erythematosus
- interstitial lung disease
- open label
- systemic sclerosis
- ankylosing spondylitis
- cell therapy